PBPK modeling and simulation in drug research and development

被引:0
|
作者
Xiaomei Zhuang [1 ]
Chuang Lu [2 ]
机构
[1] State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacology and Toxicology
[2] Department of DMPK,Biogen,Inc.
关键词
PBPK; PK prediction; Absorption; Metabolism; Drug–drug interaction; Special population;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Physiologically based pharmacokinetic(PBPK) modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data.It can also explore the effects of various physiologic parameters such as age,ethnicity,or disease status on human pharmacokinetics,as well as guide dose and dose regiment selection and aid drug–drug interaction risk assessment.PBPK modeling has developed rapidly in the last decade within both the field of academia and the pharmaceutical industry,and has become an integral tool in drug discovery and development.In this mini-review,the concept and methodology of PBPK modeling are briefly introduced.Several case studies were discussed on how PBPK modeling and simulation can be utilized through various stages of drug discovery and development.These case studies are from our own work and the literature for better understanding of the absorption,distribution,metabolism and excretion(ADME) of a drug candidate,and the applications to increase efficiency,reduce the need for animal studies,and perhaps to replace clinical trials.The regulatory acceptance and industrial practices around PBPK modeling and simulation is also discussed.
引用
收藏
页码:430 / 440
页数:11
相关论文
共 50 条
  • [1] PBPK modeling and simulation in drug research and development
    Zhuang, Xiaomei
    Lu, Chuang
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 430 - 440
  • [2] Modelling and PBPK Simulation in Drug Discovery
    Hannah M. Jones
    Iain B. Gardner
    Kenny J. Watson
    The AAPS Journal, 2009, 11 : 155 - 166
  • [3] Modelling and PBPK Simulation in Drug Discovery
    Jones, Hannah M.
    Gardner, Iain B.
    Watson, Kenny J.
    AAPS JOURNAL, 2009, 11 (01): : 155 - 166
  • [4] Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation
    Franchetti, Yoko
    Nolin, Thomas D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S36 - S51
  • [5] PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment
    Ferreira, Abigail
    Lapa, Rui
    Vale, Nuno
    PROCESSES, 2021, 9 (11)
  • [6] Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development
    Shardlow, Carole E.
    Generaux, Grant T.
    Patel, Aarti H.
    Tai, Guoying
    Thuy Tran
    Bloomer, Jackie C.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 1994 - 2003
  • [7] A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam
    A. R. Maharaj
    J. S. Barrett
    A. N. Edginton
    The AAPS Journal, 2013, 15 : 455 - 464
  • [8] A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam
    Maharaj, A. R.
    Barrett, J. S.
    Edginton, A. N.
    AAPS JOURNAL, 2013, 15 (02): : 455 - 464
  • [9] Pediatric Cardiovascular Drug Development and Research: Integration of Modeling and Simulation as One Future Direction
    Laer, Stephanie
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (03) : 217 - 227
  • [10] Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001
    Nothnagel, Lisa
    Jung, Fabian
    Rossmanith, Tanja
    Thurn, Manuela
    Ashtikar, Mukul
    Geisslinger, Gerd
    Parnham, Michael J.
    Wacker, Matthias G.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2019, 134 : 144 - 152